Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.

Singh D, Beeh KM, Colgan B, Kornmann O, Leaker B, Watz H, Lucci G, Geraci S, Emirova A, Govoni M, Nandeuil MA.

Respir Res. 2019 Aug 9;20(1):180. doi: 10.1186/s12931-019-1142-7.

2.

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018.

3.

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.

Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, Hogg A, Wajdner H, Yang S, Robertson J, Hamblin JN, Ludwig-Sengpiel A, Kornmann O, Hessel EM.

J Pharmacol Exp Ther. 2018 Dec;367(3):405-413. doi: 10.1124/jpet.118.249516. Epub 2018 Sep 14.

PMID:
30217958
4.

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.

Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1015-27. doi: 10.5414/CP202446.

5.

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.

N Engl J Med. 2015 May 21;372(21):1987-95. doi: 10.1056/NEJMoa1411776. Epub 2015 May 17.

6.

The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.

Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.

Pulm Pharmacol Ther. 2015 Jun;32:101-8. doi: 10.1016/j.pupt.2015.02.008. Epub 2015 Mar 3.

7.

Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.

Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G.

Pulm Pharmacol Ther. 2014 Aug;28(2):149-53. doi: 10.1016/j.pupt.2014.03.003. Epub 2014 Mar 18.

8.

Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.

Bateman ED, Kornmann O, Ambery C, Norris V.

Pulm Pharmacol Ther. 2013 Oct;26(5):581-7. doi: 10.1016/j.pupt.2013.03.015. Epub 2013 Mar 26.

PMID:
23538170
9.

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.

Respir Med. 2013 Feb;107(2):223-32. doi: 10.1016/j.rmed.2012.10.022. Epub 2012 Dec 6.

10.

Safety of indacaterol in the treatment of patients with COPD.

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:477-92. doi: 10.2147/COPD.S23816. Epub 2011 Sep 22.

11.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.

J Allergy Clin Immunol. 2011 Aug;128(2):315-22. doi: 10.1016/j.jaci.2011.06.004.

PMID:
21807250
12.

Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD.

Taube C, Rydzy L, Eich A, Korn S, Kornmann O, Sebastian M, Jörres RA, Buhl R.

Respir Med. 2011 Feb;105(2):316-21. doi: 10.1016/j.rmed.2010.11.017. Epub 2010 Dec 9.

13.

Measurement of exhaled nitric oxide: comparison of different analysers.

Korn S, Telke I, Kornmann O, Buhl R.

Respirology. 2010 Nov;15(8):1203-8. doi: 10.1111/j.1440-1843.2010.01847.x.

PMID:
20920124
14.

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.

Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.

Eur Respir J. 2011 Feb;37(2):273-9. doi: 10.1183/09031936.00045810. Epub 2010 Aug 6.

15.

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.

Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R.

Respir Med. 2009 Nov;103(11):1725-31. doi: 10.1016/j.rmed.2009.05.002. Epub 2009 Jun 9.

16.

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.

Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.

Respir Med. 2008 Jul;102(7):1033-44. doi: 10.1016/j.rmed.2008.02.001. Epub 2008 May 13.

17.

Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease.

Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, Holz O, Buhl R, Magnussen H, Jörres RA.

Pulm Pharmacol Ther. 2008;21(2):409-17. Epub 2007 Nov 9.

PMID:
18063399
18.

Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions.

Korn S, Beier J, Heilmann C, Kornmann O, Buhl R, Michael Beeh K.

Respir Med. 2005 Dec;99(12):1595-9. Epub 2005 Apr 26.

19.
20.
21.

Stability of glutathione in induced sputum: impact of freezing.

Beier J, Beeh KM, Kornmann O, Buhl R.

Respiration. 2003 Sep-Oct;70(5):523-7.

PMID:
14665779
22.
23.

Sputum induction leads to a decrease of exhaled nitric oxide unrelated to airflow.

Beier J, Beeh KM, Kornmann O, Buhl R.

Eur Respir J. 2003 Aug;22(2):354-7.

24.

Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis.

Beeh KM, Beier J, Kornmann O, Buhl R.

Sarcoidosis Vasc Diffuse Lung Dis. 2003 Jun;20(2):138-43.

PMID:
12870724
27.
28.

Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4.

Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ.

Chest. 2003 Apr;123(4):1240-7.

PMID:
12684317
29.

Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD.

Beeh KM, Beier J, Kornmann O, Mander A, Buhl R.

Chest. 2003 Mar;123(3):778-83.

PMID:
12628878
30.

Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease.

Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R; Global Initiative for Obstructive Lung Disease.

Respiration. 2003 Jan-Feb;70(1):67-75.

PMID:
12584394
31.

Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis.

Beeh KM, Beier J, Haas IC, Kornmann O, Micke P, Buhl R.

Eur Respir J. 2002 Jun;19(6):1119-23.

32.

[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].

Beeh KM, Beier J, Kornmann O, Wiewrodt R, Buhl R; SAS 40011-Studiengruppe.

Pneumologie. 2002 Feb;56(2):91-7. German.

PMID:
11842346
34.
35.

[Correlation of plasma glutathione and total IgE level: evidence for a regulatory role of antipxodants in vivo].

Beeh KM, Micke P, Kornmann O, Buhl R.

Pneumologie. 2000 Dec;54(12):569-71. German.

PMID:
11199114

Supplemental Content

Loading ...
Support Center